Here you will find archived C-Path news events. Please feel free to browse the documents and news releases below to learn more about what have been doing here at the Critical Path Institute.
Tucson, Arizona, December 9, 2010 - Alfred M. Cohen, MD, FACS, FASCRS, has joined Critical Path Institute (C-Path) as Director of its Cancer Biosignature Programs.
Tucson, Arizona, December 9, 2010 - Martha Brumfield, PhD, has joined Critical Path Institute (C-Path) as Director of International Programs.
Marc Cantillon, MD, has joined Critical Path Institute as Executive Director of one of its major consortia, the Coalition Against Major Diseases (CAMD). Dr.Cantillon has a 15+year background in government,academic and pharmaceutical industry translational research, drug development and clinical research.
Thorir D. Bjornsson, MD, PhD, has joined Critical Path Institute as a member of its Board of Directors, and will also lead one of its major consortia, the Critical Path to TB Drug Regimens, Regulatory Science Consortium (CPTR).
Science Foundation Arizona selects Tucson based Critical Path Institute and collaborator, Roche's Ventana Medical Systems, to develop innovative national resource for clinical research standardization
The CDISC Board of Directors and Dr. Rebecca Kush, President & CEO are pleased to announce three exceptional keynote speakers to introduce this year's event: Dr. Doug Fridsma, acting director of the Office of Interoperability and Standards in the Office of the National Coordinator for Health Information Technology; Dr. Theresa M. Mullin, Ph.D., Director, Office of Planning and Informatics, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA) and Dr. Raymond L. Woosley, Founder and Chief Executive Officer of the Critical Path Institute (C-Path).
Pharmacometrics as a Discipline Is Entering the "Industrialization" Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success
For the first time, new biomarker tests to detect drug-induced kidney injury have been accepted by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).
A new database of more than 4,000 Alzheimer's disease patients who have participated in 11 industry-sponsored clinical trials will be released today by the Coalition Against Major Diseases (CAMD).
A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute's Predictive Safety Testing Consortium's evaluation of seven kidney biomarkers for use in drug safety assessment.
Raymond L. Woosley, MD, PhD, President/CEO of Tucson-based Critical Path Institute (CPI), was recently presented with the prestigious 2010 PhRMA Foundation Award in Excellence in Clinical Pharmacology at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT).
Stephen Joel Coons, PhD, Joins as Director of the newly formed Patient-Reported Outcomes Consortium
FDA applauds effort to take years off development of much needed TB treatments
Governor Jan Brewer today appointed one new member to the Arizona Board of Regents, Tucson resident Rick Myers.
Recently the Carcinogenicity Working Group of The Critical Path Institute's Predictive Safety Testing Consortium used TaqMan® Gene Expression Assays and Arrays to both validate and extend existing microarray data generated to predict non-genotoxic carcinogens that chemically induce hepatic tumorigenicity in rats.
Beatriz Rendón and Steven Broadbent have joined the Critical Path Institute (C-Path) as the independent non-profit organization continues to grow and execute its mission of creating collaborations that result in improved testing methods that accelerate development of safe, new medical products.
This week, Inside Tucson Business debuts a new monthly feature which profiles the work of young scientists. The idea is to showcase the work and projects of budding scientists, engineers, doctors and researchers.
Richard T. Myers, a former senior executive with engineering expertise at IBM, has been named Chief Operating Officer of the nonprofit Critical Path Institute, its founder and CEO, Dr. Ray Woosley, announced.
In clinical practice, personalized medicine refers to the use of new methods of molecular analysis to better manage a patient's disease...
The November 2008 issue of Reader's Digest lists 18 big ideas to fix healthcare now and the Critical Path Insitute is listed as number 7.
The Critical Path Institute (C-Path), has been awarded a $9 million investment grant from Science Foundation Arizona (SFAz).
Companies receive go ahead from FDA and EMEA to use new improved tests when assessing safety of new drugs.
In the first use of a framework allowing submission of a single application to the two agencies, the Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) worked together to allow drug companies to submit the results of seven new tests that evaluate kidney damage during animal studies of new drugs.
The Food and Drug Administration is poised to throw its support behind a powerful new method of predicting the safety of experimental drugs, a step that could help pharmaceutical companies bring treatments to market more quickly - and reduce patients' risk.
A Tucson-based research institute says it is improving the safety of a widely used blood thinning drug.
Variations of a gene that determines a person's sensitivity to warfarin are important in determining the initial doses of the anti-clotting drug, researchers report.
Dr. Alastair J.J. Wood, drug development authority, frequent advisor to the Food and Drug Administration (FDA) and former Assistant Vice Chancellor for Research at Vanderbilt University was recently named to the Board of Directors of the Critical Path Institute.
The Critical Path Institute today announced that Peter B. Corr, Ph.D., has joined its Board of Directors. Dr. Corr has more than 30 years of pharmacology and pharmaceutical development experience as both an academician and a senior executive in the pharmaceutical industry.
Thanks to C-Path's role as an independent, neutral third party, it has been successful in bringing together scientists from the FDA, the industry it regulates and academia.
The Critical Path Institute (C-Path) announced the receipt of a $4 million grant from the Agency for Healthcare Research and Quality (AHRQ) to continue support for its Arizona Center for Education and Research on Therapeutics (AzCERT).
The Critical Path Institute (C-Path) and Ventana Medical Systems, Inc. (Ventana) (NASDAQ: VMSI) today released additional information about C-Path's $2.1 million grant from Science Foundation Arizona (SFAz) to fund a collaboration project with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) to develop a standard testing and evaluation process for companion diagnostics and their associated targeted cancer therapies.
Science Foundation Arizona (SFAz), through its Strategic Research Group (SRG) program, today announced that it is granting nearly $10 million to eight outstanding research collaborations throughout the state.
To address the issues surrounding a decade-long decrease in the number of new drug approvals, the U.S. Food and Drug Administration (FDA) in 2004 published a report titled Challenge and Opportunity on the Critical Path to New Medical Products.
William Mattes of C-Path spoke at the Arizona Pavillion May 8th 2007 about the Predictive Safety Testing Consortium.
Developing a new drug is a costly and time-intensive venture. It often takes years to safely develop, test, and ultimately gain Food and Drug Administration approval to bring the drugs to market.
President and CEO of The Critical Path Institute (C-Path) provided testimony and answered questions about drug development yesterday at the Committee on Energy and Commerce's Subcommittee Hearing on Oversight and Investigations entitled "The Adequacy of FDA Efforts to Assure the Safety of the Drug Supply."
Rosetta Biosoftware announced today that The Critical Path Institute (C-Path) adopted the Rosetta Resolver® system for C-Path's Predictive Safety Testing Consortium.
The Critical Path Institute (C-Path) today announced seven new members that have recently joined the Predictive Safety Testing Consortium (PSTC)...
A little-noticed 2004 report from the Food and Drug Administration contained a bombshell. Although spending on research and development had been rising for the previous decade, applications for new drugs and medical products had been falling.
The Critical Path Institute (C-Path) has received $675,000 from the US Food and Drug Administration (FDA) for the first year of what is anticipated to be a multi-year, multi phased research program in cardiovascular disease.
The Critical Path Institute (C-Path), today announced the appointment of Jeffrey Cossman, M.D., an internationally recognized expert in molecular pathology, to the position of Chief Scientific Officer.
The federal government is backing the first potential cure for valley fever, a serious lung disease that has spiked in recent years and afflicted thousands of Arizonans.
The Tucson-based Critical Path Institute on Thursday announced an unprecedented agreement with eight major pharmaceutical companies to share drug-testing methods in an effort to improve drug safety.
The Food and Drug Administration (FDA) and The Critical Path Institute (C-Path) today announced the formation of the Predictive Safety Testing Consortium between C-Path and five of Americaâ€™s largest pharmaceutical companies to share internally developed laboratory methods to predict the safety of new treatments before they are tested in humans.
The retired head of research at the University of Arizona has joined the Tucson-based Critical Path Institute, a UA- and FDA-affiliated drug research institute, as head of its affiliations with research universities.
We all remember the Vioxx scare and authorities say it could happen again. However, the FDA is stepping up its efforts to improve the safety of prescription drugs and here in Tucson a research group is piloting a program to examine and detect them carefully.